ProCE Banner Activity

BRIGHTE Update: Wk 240 Results From Phase III Study of Fostemsavir + OBT in Heavily Treatment–Experienced People on Failing ART Regimens

Conference Coverage
Slideset

HIV-1 RNA suppression rates were durable and CD4+ cell counts continued to improve through Week 240 in this difficult-to-treat population receiving fostemsavir plus optimized background therapy.

Released: October 19, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare